Joanne Webb
Eli Lilly (United Kingdom)(GB)
Publications by Year
Research Areas
Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Mosquito-borne diseases and control, Heart Failure Treatment and Management, Dialysis and Renal Disease Management
Most-Cited Works
- → Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND , LEADER and SUSTAIN ‐6 to the real‐world type 2 diabetes population in the United Kingdom(2021)17 cited
- → Temporal variation of renal function in people with type 2 diabetes mellitus: A retrospective UK clinical practice research datalink cohort study(2019)10 cited
- → Therapeutic inertia related to the injectable glucagon‐like peptide‐1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care(2023)7 cited
- → DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice(2019)3 cited
- → CATALIN, QUINONES, AND CATARACT(1974)1 cited
- → Tropical Ulcers and Penicillin(1946)
- → Corrigendum to “DPP-4 Inhibitor Dose Selection According to Manufacturer Specifications: A Contemporary Experience From UK General Practice” [Clinical Therapeutics 41 (8) (2019) 1622–1630](2020)